Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Safety and effectiveness of brentuximab vedotin in Chinese adult patients with classical Hodgkin's lymphoma: Results from a multicenter, prospective, observational, real-world study

View Full Paper
Ask AI
Bookmark
Share

Authors

CLChuanxu LiuWHWenyang HuangOBOu Bai

Discussion

Loading...

Member takes

Overview

Multicenter study shows complete response in classical Hodgkin lymphoma patients, implying robust safety profile and effectiveness of brentuximab vedotin.

Key Points

  • The research evaluates the safety and effectiveness of brentuximab vedotin in Chinese patients with classical Hodgkin lymphoma.
  • Multicenter, prospective, observational real-world study
  • Included 512 patients with classical Hodgkin lymphoma
  • Evaluated adverse events, dose intensity, and survival outcomes
  • Adverse events reported in 67.2% of patients, including 8.6% serious adverse events
  • Complete response rate was 59.9% in newly diagnosed patients
  • Overall survival rate was 100% in early-stage disease after 1 year

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d722https://doi.org/10.1182/blood-2025-7135
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world, multicenter study of brentuximab vedotin-based regimens in Chinese patients with relapsed/refractory Hodgkin lymphoma2025
  2. 2Safety and effectiveness of brentuximab vedotin in Chinese patients with CD30-positive lymphomas: A multicenter real-world analysis2025
  3. 3Updated real-world outcomes with brentuximab vedotin in lymphoma patients: A multicenter, retrospective study from China2025
  4. 4Real-world Effectiveness and Safety of Brentuximab Vedotin: A Retrospective Cohort Study from a Tertiary Care Hospital2026
  5. 5Efficacy and safety of brentuximab vedotin in relapsed or refractory diffuse large B-cell lymphoma: A systematic review and meta-analysis.2026